Aducanumab

Aducanumab Recent News

Biogen Delays Regulatory Filing For Approval Of Alzheimer's Drug, Shares Slump
Biogen Inc (NASDAQ: BIIB) shares were under pressure Wednesday following the release of the biotech's first-quarter report, including the statement that Biogen's BLA filing for its Alzheimer's drug will be delayed.
Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says
Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation
Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response
Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade
Cramer Makes The Case Why Biogen's Stock Could Double In Value
Biogen Analysts Debate About-Face On Aducanumab: 'Path To Market An Uphill Battle'
Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'
Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study
After Biogen's Alzheimer's Update, Wall Street Reacts
Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs
Biogen's Best-In-Class R&D Earn Makes It A Buy
Biogen's Core Business Impresses While Potential Alzheimer's Catalyst Looms
19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug
Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail
Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects
Experts React To Concerning Alzheimer's News From Lilly
Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug
Wall Street Mixed On Biogen Before Earnings
Piper Jaffray On Biogen Downgrade: '6 MG Data Does Not Inspire Confidence…Even More Speculative Than Before'
Disappointing Drug News Sends Biogen And XOMA Shares Down
RBC Says Biogen Can Move 10% After BIIB-037 Data Is Revealed